SecBot SecBot
SECBOTREPLAY Home › Report › HCM

HCM · HUTCHMED reported H1 2026 results with total revenue essentially flat…

HUTCHMED (China) Ltd · 6-K filed Jul 30, 2026 at 07:18 ET

At the news

BULLISHIMPACT 6/10

6-K filed Jul 30, 2026 at 07:18 ET

HUTCHMED reported H1 2026 results with total revenue essentially flat at $278.3M (vs $277.7M in H1 2025) but a strong 23% increase in Oncology/Immunology marketed product revenue to $121.4M, driven by ELUNATE (+41%), SULANDA (+45%), and FRUZAQLA ex-US (+70%). Net income attributable to HUTCHMED was $15.9M, down sharply from $455.0M in H1 2025 which included a $416.3M gain on the SHPL divestment. The company reiterated full-year 2026 Oncology/Immunology revenue guidance of $330M-$450M and ended the period with $1.37B in cash. Key pipeline catalysts include expected SAFFRON and SANOVO Phase III readouts in H2 2026 and two sovleplenib NDAs under priority review in China.

  • Total revenue H1 2026: $278.3M (flat vs $277.7M H1 2025; -4% actual, +4% CER)
  • Oncology/Immunology consolidated revenue: $162.3M, up 13% (10% CER)
  • Net income attributable to HUTCHMED: $15.9M ($0.02/share basic EPS vs $0.53 in H1 2025, which included $416.3M SHPL gain)
  • Cash & short-term investments: $1.37B as of June 30, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access